Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Mission Viejo, California • Orange, California + 26 more

Conditions: Rheumatoid Arthritis
Interventions: Golimumab, Methotrexate, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 20
States / cities: Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, RO5024048, danoprevir, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 19
States / cities: La Jolla, California • Long Beach, California • Sacramento, California + 15 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Dothan, Alabama • Gilbert, Arizona + 119 more

Conditions: Cardiovascular Diseases
Interventions: Psychosocial Intervention, Structural Intervention, Traditional Psychosocial+Structural, Integrated Psychosocial+Structural; Behavioral · Other
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 25 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Sleep Apnea, Obstructive Sleep Apnea, Postoperative Complications
Interventions: Ketamine, Control; Drug · Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Oprozomib, Sorafenib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Burlington, California • Denver, Colorado • Miami, Florida + 3 more

Conditions: HIV Infections
Interventions: Maraviroc (UK-427,857), Optimized Background Therapy, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 20
States / cities: Sacramento, California • San Francisco, California • Auroa, Colorado + 14 more

Conditions: HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion
Interventions: PREVENT - BCT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Interventions: EsoCheck®, EsoGuard®; Device · Diagnostic Test
Lead sponsor: Lucid Diagnostics, Inc.; Industry
Eligibility: Not listed
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Pediatric Disorder
Interventions: Acetaminophen, Ibuprofen; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 3 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Hiv, HIV/AIDS, HIV Infections, AIDS, AIDS and Infections, Aids/Hiv Problem
Interventions: N-803 and bNAbs, haNK™ Cells; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Periodontal Diseases
Interventions: Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatocellular Carcinoma
Interventions: Lenvatinib, Transcatheter Arterial Chemoembolization; Drug · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adolescent Behavior, Group, Peer, Violence, Non-accidental, Violence, Sexual, Violence, Domestic, Emotional Abuse, Coping Skills, Communication, Personal
Interventions: Creating Peace, Job Readiness; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 19 Years
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Renal Failure (ARF), Acute Tubular Necrosis
Interventions: QRX-3; Drug
Lead sponsor: Ebima Clifford Okundaye; Industry
Eligibility: 10 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rosharon, Texas

Conditions: Meniscus Tear, Meniscus; Derangement, Meniscus Lesion, Meniscus Disorder
Interventions: Fisetin, Placebo oral capsule; Drug
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Adhd
Interventions: RELAX; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 11 Years to 16 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Hemophilia A
Interventions: Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC); Biological
Lead sponsor: Emory University; Other
Eligibility: Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Heart Failure and Reduced Ejection Fraction
Interventions: LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 81
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more

Conditions: Hypertension
Interventions: EHMI, Nurse Educator + EHMI; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions: Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
Interventions: Dasatinib, Ganitumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Conditions: Cancer
Interventions: Personalized Smartwatch, Facebook Health Education; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 50 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Nutrition360: Moving to Integrated and Holistic Disease Prevention Among Underserved Mississippians

Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

PREVENT HPV-Related Cancers - BootCamp Translation

Lucid Registry Study

Comparing the Difference in Pain Control in the Pediatric General Surgery Population: to Alternate or Combine Acetaminophen and Ibuprofen?

N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV

Amnion-Chorion Allograft Barrier Used for Root Surface and Guided Tissue Regeneration

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Creating Peace: Community-based Youth Violence Prevention to Address Racism and Discrimination

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair

Improving Emotion Regulation in Adolescents With ADHD

Treatment of Hemophilia A Patients With FVIII Inhibitors

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Northwestern University and Access Community Health Network Medication Education Study

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Implementing Personalized Exercise Prescriptions Through Mobile Health in the Elderly Cancer Survivors